Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET
電話會議定於4月1日星期一舉行st，2024 年，美國東部時間下午 4:30
NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024.
紐約州紐約/ACCESSWIRE/2024年3月25日/生物製藥創新者Protagenic Therapeutics, Inc.（納斯達克股票代碼：PTIX）宣佈，該公司計劃舉行首次投資者業績電話會議，討論計劃當天提交的2023財年10K表中包含的業績以及2024財年的展望。
The Company plans to hold its earnings call, open to the public, at 4:30 pm ET on Monday, April 1st, to discuss the results of its Q4 and FY 2023, which it plans to publish in its Form 10K to be filed with the SEC that day. On the call, management also plans to discuss the company's outlook for FY 2024, including expectations for additional data readouts from the ongoing PT00114 clinical trial.
該公司計劃於美國東部時間4月1日星期一下午 4:30 舉行向公衆開放的業績電話會議st，討論其第四季度和2023財年的業績，該公司計劃在當天向美國證券交易委員會提交的10K表格中公佈該業績。在電話會議上，管理層還計劃討論該公司2024財年的展望，包括對正在進行的 PT00114 臨床試驗獲得更多數據的預期。
Participants in the discussion about the outlook for the trial will be Robert B. Stein, MD, PhD, Chief Medical Officer, and Andrew Slee, PhD, Chief Operating Officer, as well as Garo H. Armen, PhD, Executive Chairman.
關於試驗前景的討論的參與者將是首席醫學官羅伯特·斯坦博士、首席運營官安德魯·斯利博士以及執行主席加羅·阿門博士。
The log-in link is: . For those wishing to participate by phone only, dial: Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 628544
登錄鏈接是:.對於那些只想通過電話參與的人，請撥打：免費電話：888-506-0062
國際：973-528-0011
參與者訪問碼：628544
About Protagenic Therapeutics, Inc.:
Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is committed to pioneering neuro-active peptides into therapeutics to mitigate stress-related disorders. For more information, visit .
關於 Protagenic Therapeutics, Inc.：
Protagenic Therapeutics, Inc.（納斯達克股票代碼：PTIX）致力於開創神經活性肽作爲緩解壓力相關疾病的療法。欲了解更多信息，請訪問。
About PT00114:
PT00114, a 41-amino-acid residue synthetic peptide, holds promise as a novel treatment for serious neuro-psychiatric conditions, including depression, anxiety, and PTSD. It is a synthetic form of the naturally-occurring brain peptide TCAP, which acts to counter the negative biochemical and behavioral effects of the stress-induced brain hormones Corticotropin Releasing Factor and Arginine-Vasopressin. Among the beneficial effects of PT00114 is the reduction of excessive circulating levels of cortisol that often are part of the response to various stressors.
關於 PT00114：
PT00114 是一種 41 氨基酸殘留的合成肽，有望成爲嚴重神經精神疾病（包括抑鬱、焦慮和創傷後應激障礙）的新療法。它是天然存在的大腦肽 TCAP 的合成形式，可抵消壓力誘導的大腦激素促腎上腺激素促腎上腺皮質激素釋放因子和精氨酸加壓素的負面生化和行爲影響。PT00114 的有益作用之一是降低過高的皮質醇循環水平，而皮質醇通常是對各種壓力反應的一部分。
Forward-Looking Statements:
This press release contains forward-looking statements concerning Protagenic Therapeutics' product candidates and clinical trial plans. These statements are subject to various risks and uncertainties. Investors are urged to exercise caution and not place undue reliance on these forward-looking statements.
前瞻性陳述：
本新聞稿包含有關Protagenic Therapeutics候選產品和臨床試驗計劃的前瞻性陳述。這些陳述受各種風險和不確定性的影響。敦促投資者謹慎行事，不要過分依賴這些前瞻性陳述。
Company Contact:
Alexander K. Arrow, MD, CFA
Chief Financial Officer
Protagenic Therapeutics, Inc. 149 Fifth Ave, Suite 500, New York, NY 10010. Tel: 213-260-4342
Email: alex.arrow@protagenic.com
公司聯繫人：
亞歷山大·阿羅，醫學博士，特許金融分析師
首席財務官
Protagenic Therapeutics, Inc. 第五大道 149 號，套房 500，紐約，紐約州 10010。電話：213-260-4342
電子郵件：alex.arrow@protagenic.com
Investor Relations Contact:
Kirin M. Smith, President, PCG Advisory, Inc. 950 Third Avenue, Suite #2700, New York, NY 10022. Tel: 646-823-8656 Email: ksmith@pcgadvisory.com
投資者關係聯繫人：
Kirin M. Smith，PCG Advisory, Inc. 總裁。第三大道950號，套房 #2700，紐約，紐約州，10022。電話：646-823-8656 電子郵件：ksmith@pcgadvisory.com
SOURCE: Protagenic Therapeutics, Inc.
來源：Protagenic Therapeutics, Inc.